Imagine

Imagine you are an **investor**

You have to pick the **best investment out of a million options**

Each question costs you over **EUR 200 to 100,000** for each option

This is what early drug R&D looks like

Picking the wrong ones will cost them **EUR 25 million**

Picking the right ones will yield **billions** and **save many lives**

Today, they can only guess

We help them **look into the future, instantly**

IridescentBio

we are

IridescentBio

Bringing more life-saving therapies to market, faster

pre-seed round



NVIDIA Inception Program

aws

IridescentBio

Situation

Developing new antibodies is costly and time consuming



>10 years

EUR 3bn cost*

4% success rate

Generating candidates

> 1.000.000 drug candidates

Selecting and improving to find a drug

Per approval

24 Programs

EUR **1bn** pre clinic

4-6 years

35% success rate to clinic

Proving safety and superior effectivity

1 approved drug

*) per approved drug (including cost of capital)

IridescentBio

Problem

The lack of predictive insights causes biopharma R&D teams to waste time and money on bad candidates



IridescentBio

Problem

Our Virtual Screening predicts which drug candidates are most likely to get to clinic by looking 4 years ahead



IridescentBio

Our Virtual Screener platform helps users make the best decisions in selecting and developing drugs

Screen for…
Affinity
Developability
Target Specificity
Formulatability



IridescentBio

Benefits

Save 20% on the development throughput time, saving, out-of-pocket, cost of capital and opportunity costs



Cost of:

Wasting first year of research	EUR 0.5-1m
Abandoning a program at optimization	EUR 10m
Cost of capital of one year delay at CMC	EUR 20-50m

Benefit of:

One year faster go-to-market	EUR 500m
Being first in a new category	EUR 5bn

IridescentBio

Traction

By deploying early modules as MVP's, we have received early feedback on our route to product-market-fit



Early MVP feedback

MVP 1

SOLVED

MVP 2

"We are currently drafting a publication based on findings with IridescentBio" *(large CRO)*

There is nothing like this

(top-5 biopharma A)

We have budget for a next POC

(top biopharma B, unsolicited)

IridescentBio

Technology

We build on the fundaments of over 100's of years of science and a major recent AI breakthrough

Computational



Schrödinger, OpenEye, Culgi



IridescentBio

AI



Isomorphic Labs, Cradle

Team

If it wasn't complex, everyone could do it. Our stellar team has a track record in solving these problems

Aart Bijkerk

Co-founder - Chief Executive Officer

- Previously TMT lead at Clearwater (corporate finance) focused on SaaS
- MSc in Business Administration

Deloitte.

CLEARWATER

Johannes Fraaije

Co-founder - Chief Science Officer

- Professor of Physical Chemistry
- Previously commercialized physics modelling with Mesodyn (sold to Biovia / Dassault Systems) and Culgi (exit to Siemens Digital)

Universiteit Leiden The Netherlands

CULGI

SIEMENS

Nicholas Tito

Head of Product

- Ph.D in Physical Chemistry
- Previously Director of Science at RheoCube

DARTMOUTH

UNIVERSITY OF CAMBRIDGE

RHEOCUBE

TU/e

MERCK

André Nunes

Chief Software Engineer

- Ph.D in computational soft matter physics, data scientist in industry
- Expertise in cloud computing / architecting
- Started his professional career as a data scientist / ML specialist

U LISBOA

RHEOCUBE

IridescentBio

We create a new category in a large, global market

EUR 200bn antibody therapeutics market with EUR 7bn outsourced R&D service

TAM: EUR 3bn
50% of all 6000 biopharma companies work on immunotherapies representing EUR 1m contracts

SAM: EUR 600m
c. 1200 novel antibody development programs live at any moment ACV: EUR 500k

SOM: EUR 120m
20% of SAM; multiple software and data providers have shown to be able to generate over EUR 100m in annual sales



Business plan

We plan to further develop our science and become the secret ingredient to antibody discovery and development



IridescentBio

Ask

We are currently raising the last EUR 600k in our pre-seed to become the secret ingredient to antibody development

Aart Bijkerk

+316 1962 8569

aart.bijkerk@iridescent.bio

IridescentBio

Friendly Cloud Experience

Product today



Instant access via web browser

Online 24/7

Easy input
Full Abs by FASTA or PDB

No model tuning / expertise required

Case Studies

Protein Binding Affinity

Proof

IridescentBio



Physicochemical model

built-in variability with pH, salt, excipients



PRODIGY Model [2]

2015

data model with physical trends

[1] **Yi et al., 2024:** https://doi.org/10.1021/acsomega.3c06996
[2] **Vangone and Bonvin, 2015:** https://doi.org/10.7554/eLife.07454

Protein Pair Data: Memphis dataset [1], composed of SPR and ITC data

Proof

Case Studies

Antibody / Target Docking Prediction

Isatuximab / CD38



IridescentBio



Experiment



	ΔG (kcal/mol)
Prodigy	-10.2
IridescentBio	-13.6
Experiment	-13.0

Daratumumab / CD38



IridescentBio



Experiment



	ΔG (kcal/mol)
Prodigy	-5.70
IridescentBio	-13.2
Experiment	-11.0

Rituximab / CD20



IridescentBio

Experiment



	ΔG (kcal/mol)
Prodigy	–9.81
IridescentBio	-12.3
Experiment	-11.1

IridescentBio

Proof

Case Studies

Formulation Stabilization

Joint study with major biopharma CRO on antibody formulation stability

<u>Acetate buffer</u>
formulation stability **decreases** with pH

<u>Histidine buffer</u>
formulation stability **increases** with pH

No Histidine



with Histidine



IridescentBio